Price Action to Note: Could Omeros Corporation See a Reversal After This Very Strong Session?

Price Action to Note: Could Omeros Corporation See a Reversal After This Very Strong Session?

The stock of Omeros Corporation (NASDAQ:OMER) is a huge mover today! About 558,968 shares traded hands. Omeros Corporation (NASDAQ:OMER) has declined 42.66% since April 4, 2016 and is downtrending. It has underperformed by 43.75% the S&P500.
The move comes after 9 months positive chart setup for the $438.37M company. It was reported on Nov, 4 by Barchart.com. We have $28.66 PT which if reached, will make NASDAQ:OMER worth $837.29 million more.

Analysts await Omeros Corporation (NASDAQ:OMER) to report earnings on November, 14. They expect $-0.30 earnings per share, up 34.78% or $0.16 from last year’s $-0.46 per share. After $-0.24 actual earnings per share reported by Omeros Corporation for the previous quarter, Wall Street now forecasts 25.00% negative EPS growth.

Omeros Corporation (NASDAQ:OMER) Ratings Coverage

Out of 6 analysts covering Omeros (NASDAQ:OMER), 6 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Omeros has been the topic of 10 analyst reports since August 10, 2015 according to StockzIntelligence Inc. Needham maintained the shares of OMER in a report on Wednesday, November 11 with “Buy” rating. As per Friday, June 3, the company rating was initiated by Cantor Fitzgerald. The firm has “Buy” rating by TH Capital given on Monday, August 10. The rating was initiated by Roth Capital with “Buy” on Monday, August 10. WBB Securities maintained the shares of OMER in a report on Tuesday, August 18 with “Strong Buy” rating. Needham maintained Omeros Corporation (NASDAQ:OMER) on Monday, August 31 with “Buy” rating. Cowen & Co maintained Omeros Corporation (NASDAQ:OMER) on Tuesday, August 18 with “Outperform” rating.

According to Zacks Investment Research, “Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros’ most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders.”

Insitutional Activity: The institutional sentiment decreased to 0.77 in Q2 2016. Its down 0.21, from 0.98 in 2016Q1. The ratio dived, as 15 funds sold all Omeros Corporation shares owned while 32 reduced positions. 13 funds bought stakes while 23 increased positions. They now own 19.91 million shares or 14.90% more from 17.33 million shares in 2016Q1.
Lpl Financial Limited Liability Company, a California-based fund reported 10,120 shares. Moreover, Voya Inv Mgmt Limited has 0% invested in Omeros Corporation (NASDAQ:OMER) for 15,996 shares. Blackrock Institutional Tru Na, a California-based fund reported 912,201 shares. Schwab Charles Mngmt Incorporated owns 65,900 shares or 0% of their US portfolio. Mufg Americas Hldgs Corp has invested 0% of its portfolio in Omeros Corporation (NASDAQ:OMER). Gradient Invests Limited Liability owns 24,471 shares or 0.03% of their US portfolio. Invesco last reported 80,525 shares in the company. State Street accumulated 0% or 881,993 shares. State Bank Of New York Mellon holds 0% or 212,829 shares in its portfolio. Bnp Paribas Arbitrage holds 1,440 shares or 0% of its portfolio. First Republic Inv Mngmt reported 53,000 shares or 0.01% of all its holdings. Next Financial Gru last reported 1,000 shares in the company. Tradewinds Llc owns 7,678 shares or 0.06% of their US portfolio. New York State Common Retirement Fund, a New York-based fund reported 114,695 shares. Jpmorgan Chase holds 128 shares or 0% of its portfolio.

Insider Transactions: Since May 16, 2016, the stock had 0 insider buys, and 5 selling transactions for $732,521 net activity. The insider Cable Thomas J. sold $34,557. Kelbon Marcia S. sold 15,900 shares worth $158,057.

Another recent and important Omeros Corporation (NASDAQ:OMER) news was published by Seekingalpha.com which published an article titled: “Encouraging News From Omeros Corporation” on October 18, 2016.

OMER Company Profile

Omeros Corporation, incorporated on June 16, 1994, is a biopharmaceutical company. The Firm is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The Company’s marketed drug product, Omidria (phenylephrine and ketorolac injection), is launched in the United States for use during cataract surgery or intraocular lens (IOL) replacement. Omidria is derived from the Company’s PharmacoSurgery platform, which is designed for patients undergoing ophthalmological, arthroscopic, urological and other surgical procedures. The Company’s PharmacoSurgery platform is based on low-dose combinations of the United States Food and Drug Administration (FDA) approved therapeutic agents delivered directly to the surgical site throughout the duration of the procedure to inhibit preemptively inflammation and other problems caused by surgical trauma, and to provide clinical assistances both during and after surgery.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment